NCT02579473
A Study of Weekly Subcutaneous Injections of SER-214 in Subjects With Parkinson's Disease (PD), to Determine the Safety, Tolerability and Pharmacokinetic (PK) Profile of SER-214
Phase: Phase 1
Role: Lead Sponsor
Start: Jan 31, 2016
Completion: Dec 31, 2023